• Je něco špatně v tomto záznamu ?

An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis

V. Novohradsky, L. Markova, H. Kostrhunova, Z. Trávníček, V. Brabec, J. Kasparkova,

. 2019 ; 9 (1) : 13327. [pub] 20190916

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028816

Conventional chemotherapy is mostly effective in the treatment of rapidly-dividing differentiated tumor cells but has limited application toward eliminating cancer stem cell (CSC) population. The presence of a very small number of CSCs may contribute to the development of therapeutic resistance, metastases, and relapse. Thus, treatment failure by developing novel anticancer drugs capable of effective targeting of CSCs is at present a major challenge for research focused on chemotherapy of cancer. Here, we show that Os(II) complex 2 [Os(η6-pcym)(bphen)(dca)]PF6 (pcym = p-cymene, bphen = bathophenanthroline, and dca = dichloroacetate), is capable of efficient and selective killing CSCs in heterogeneous populations of human breast cancer cells MCF-7 and SKBR-3. Notably, its remarkable submicromolar potency to kill CSCs is considerably higher than that of its Ru analog, [Ru(η6-pcym)(bphen)(dca)]PF6 (complex 1) and salinomycin, one of the most selective CSC-targeting compounds hitherto identified. Furthermore, Os(II) complex 2 reduces the formation, size, and viability of three-dimensional mammospheres which more closely reflect the tumor microenvironment than cells in traditional two-dimensional cultures. The antiproliferation studies and propidium iodide staining using flow cytometry suggest that Os(II) complex 2 induces human breast cancer stem cell death predominantly by necroptosis, a programmed form of necrosis. The results of this study demonstrate the promise of Os(II) complex 2 in treating human breast tumors. They also represent the foundation for further preclinical and clinical studies and applications of Os(II) complex 2 to comply with the emergent need for human breast CSCs-specific chemotherapeutics capable to treat chemotherapy-resistant and relapsed human breast tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028816
003      
CZ-PrNML
005      
20210114155206.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-49774-x $2 doi
035    __
$a (PubMed)31527683
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Novohradsky, Vojtech $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
245    13
$a An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis / $c V. Novohradsky, L. Markova, H. Kostrhunova, Z. Trávníček, V. Brabec, J. Kasparkova,
520    9_
$a Conventional chemotherapy is mostly effective in the treatment of rapidly-dividing differentiated tumor cells but has limited application toward eliminating cancer stem cell (CSC) population. The presence of a very small number of CSCs may contribute to the development of therapeutic resistance, metastases, and relapse. Thus, treatment failure by developing novel anticancer drugs capable of effective targeting of CSCs is at present a major challenge for research focused on chemotherapy of cancer. Here, we show that Os(II) complex 2 [Os(η6-pcym)(bphen)(dca)]PF6 (pcym = p-cymene, bphen = bathophenanthroline, and dca = dichloroacetate), is capable of efficient and selective killing CSCs in heterogeneous populations of human breast cancer cells MCF-7 and SKBR-3. Notably, its remarkable submicromolar potency to kill CSCs is considerably higher than that of its Ru analog, [Ru(η6-pcym)(bphen)(dca)]PF6 (complex 1) and salinomycin, one of the most selective CSC-targeting compounds hitherto identified. Furthermore, Os(II) complex 2 reduces the formation, size, and viability of three-dimensional mammospheres which more closely reflect the tumor microenvironment than cells in traditional two-dimensional cultures. The antiproliferation studies and propidium iodide staining using flow cytometry suggest that Os(II) complex 2 induces human breast cancer stem cell death predominantly by necroptosis, a programmed form of necrosis. The results of this study demonstrate the promise of Os(II) complex 2 in treating human breast tumors. They also represent the foundation for further preclinical and clinical studies and applications of Os(II) complex 2 to comply with the emergent need for human breast CSCs-specific chemotherapeutics capable to treat chemotherapy-resistant and relapsed human breast tumors.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádory prsu $x farmakoterapie $x patologie $7 D001943
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a chloracetáty $x farmakologie $7 D062845
650    _2
$a komplexní sloučeniny $x farmakologie $7 D056831
650    _2
$a cymeny $x farmakologie $7 D000081007
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nekroptóza $x účinky léků $7 D000079302
650    _2
$a nekróza $x metabolismus $7 D009336
650    _2
$a lokální recidiva nádoru $x patologie $7 D009364
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $7 D014411
650    _2
$a organoplatinové sloučeniny $x farmakologie $7 D009944
650    _2
$a osmium $x farmakologie $7 D009992
650    _2
$a fenantroliny $x farmakologie $7 D010618
650    _2
$a nádorové mikroprostředí $x účinky léků $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Markova, Lenka $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
700    1_
$a Kostrhunova, Hana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
700    1_
$a Trávníček, Zdeněk $u Division of Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
700    1_
$a Brabec, Viktor $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic. Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
700    1_
$a Kasparkova, Jana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic. jana@ibp.cz.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 13327
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31527683 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155204 $b ABA008
999    __
$a ok $b bmc $g 1609151 $s 1119996
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 1 $d 13327 $e 20190916 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...